Scientists uncover how cancer cells hijack T-cells, making it harder for the body to fight back
Research led by the Chiba Cancer Center Research Institute in Japan has discovered a surprising way cancer evades the immune ...
Medscape3d
How New Research Is Redefining Melanoma Treatment
Research has introduced daromun, therapeutic vaccines, and novel combinations for metastatic melanoma, reshaping the ...
BioSpace13d
5 Novel FDA Approvals Notched in 2024
Among the 55 novel drugs that crossed the regulatory finish line last year were notable new mechanisms of action, coming ...
Peninsula biotech company sues insurance company to cover patients' injuries in clinical trials
A Bay Area biotech is suing its insurance company to cover costs associated with patients allegedly injured during clinical ...
A grim prognosis, a gamble and one patient’s fight to defy cancer
After a Stage 4 cancer diagnosis and a prognosis of 16 months to live, Katie Doble didn’t know whether she should plan her ...
The Hoya12d
GU Hospital Rolls Out Breakthrough Melanoma Treatment
The MedStar Georgetown University Hospital began implementing a new treatment for metastatic melanoma that fights a patient’s ...
News Medical on MSN13d
New drug cocktail enhances CAR-T cells for cancer treatment
Preclinical research findings from the University of North Carolina Lineberger Comprehensive Cancer Center identified a cocktail of three different drugs that can be used to generate more robust ...
Lisata, WARPNINE announces preliminary results from Phase 1b/2 iLSTA trial
Lisata Therapeutics (LSTA) and WARPNINE announced encouraging preliminary results from the Phase 1b/2a iLSTA trial evaluating certepetide, ...
Iovance Biotherapeutics Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) ("Iovance" or the “Company”), a biotechnology company focused on innovating, developing, and delivering novel polyclonal tumor infiltrating lymphocyte ...